Pharmaceutical Technology
MARCH 20, 2023
The collaboration, under a sponsored research agreement, will focus on mRNA vaccines that can help in modulating the normal immune response of the body for the treatment of certain autoimmune diseases as well as allergic conditions. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Pharmaceutical Technology
DECEMBER 8, 2022
Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 17, 2023
CAR-T therapies are based on the patient’s immune cell modification and can express artificial chimeric receptors that can identify and remove tumour cells. This therapy is expected to be an improvement over CAR-T in relapsed patients, especially those who have less number of normal T lymphocytes.
Pharmaceutical Technology
DECEMBER 5, 2022
mRNA technology is projected to offer a new generation of vaccines that direct specific cells to generate proteins that are detected by the immune system to develop a defence. Additionally, the hub could bring more capabilities, supply-chain expertise and clinical assessments to the region.
Pharmaceutical Technology
DECEMBER 1, 2022
A clinical-stage biopharmaceutical firm, Liminatus focuses on the development of new therapies for cancer that utilises the immune system of the body to detect and fight cancer cells. It can induce immune responses against Guanylyl Cyclase C (GCC) expressing colorectal, pancreatic, gastric and oesophageal cancers.
The FDA Law Blog
APRIL 8, 2024
It also noted that last year, FDA hosted a two-day public workshop and published a white paper on the regulatory framework for Artificial Intelligence in drug manufacturing, in addition to other efforts. Like many of us, OPQ seems intent on trying to keep up with how technology can/will impact pharmaceutical quality.
Pharmaceutical Technology
JANUARY 10, 2023
The collaboration will combine 3T Biosciences’ 3T- T-Cell Receptor Antigen and Cross-Reactivity Engine (TRACE) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining compounds that are directed towards cancer cells and target immune cells.
Expert insights. Personalized for you.
98 
Let's personalize your content